2024. The changing landscape of mineralocorticoid receptor antagonists – finerenone in cardiovascular and renal health. Prospects in Pharmaceutical Sciences. 22, 1 (Feb. 2024), 11–15. DOI:https://doi.org/10.56782/pps.181.